Cardioprotective Effects of Mitochondria-Targeted Peptide SBT-20 in two Different Models of Rat Ischemia/Reperfusion.

Abstract

Dysfunctional mitochondria are considered to be the major source of intracellular reactive oxygen species and play a central role in the pathophysiology of myocardial ischemia/reperfusion. This study sought to determine effects of mitochondria-targeted cytoprotective peptide SBT-20 on myocardial infarct size in two different models of ischemia/reperfusion. For in vivo studies, anesthetized Sprague Dawley rats were subjected to 30min of coronary artery occlusion followed by 3h of reperfusion. Rats received saline (control), low dose SBT-20 (0.3mg/kg/h) or high dose SBT-20 (3mg/kg/h) treatment (n=15 rats in each group). Saline or SBT-20 were delivered into the jugular vein starting 5min after coronary artery occlusion and were continued for one hour post coronary artery reperfusion. Body temperature, heart rate and blood pressure were monitored during the procedure. At the end of 3h reperfusion, the ischemic risk area, no-reflow area, and infarct size were measured. In separate in vitro studies, isolated rat hearts were exposed to 20min global ischemia, followed by SBT-20 administration (1μM) or no SBT-20 (control) throughout the 2h reperfusion. In vitro studies were conducted in cells and heart mitochondria to ascertain the mitochondrial effects of SBT-20 on mitochondrial respiration and reactive oxygen species production. In the in vivo study, the ischemic risk areas (as a percentage of the left ventricle) were similar among the saline (49.5±2.3%), low dose SBT-20 (48.6±2.1%), and high dose SBT-20 groups (48.7±3.0%). Treatment with SBT-20 significantly reduced infarct size ( as a percentage of risk area) in low dose (62.1±4.4%) and high dose (64.0±4.9%) compared with saline treatment (77.6±2.6%, p=0.001 for both doses). There was no difference in infarct size between low and high dose SBT-20 treatment. The no-reflow areas (as a percentage of the risk area) were comparable among the saline (23.9±1.7%), low dose SBT-20 (23.7±2.8%), and high dose groups (25.0±2.1%). Body temperature, heart rate and blood pressure were comparable among the 3 groups at baseline, during ischemia, and at the end of 3h of reperfusion. In the in vitro study, infarct size was reduced from 43.3±2.6% in control group (n=11) to 17.2±2.8% in the SBT-20 treatment group (n=5, p<0.05). There were no benefits of SBT-20 on recovery of left ventricular developed pressure, coronary flow, or maximal rates of contraction/relaxation. In cell studies, treatment with SBT-20 significantly improved maximal mitochondrial respiration in response to an H2O2 challenge. In isolated mitochondria, reactive oxygen species production was significantly blunted following treatment with SBT-20. In summary, SBT-20 significantly reduced infarct size in two different models of myocardial injury, but did not affect hemodynamics or no-reflow area in rat heart. The reduction in injury is postulated to involve stabilization of mitochondrial function and reduced mitochondrial production of ROS.